Tag: Novo Nordisk

BusinessHealthcare

Novo Nordisk’s Patent Lapse Opens Door for Generic GLP-1 Competition in Canadian Market

In a surprising regulatory development, Novo Nordisk allegedly failed to maintain patent protection for its blockbuster drug semaglutide in Canada. The oversight could enable generic competition years earlier than expected in one of the world’s largest markets for the GLP-1 medication.

Patent Maintenance Oversight Creates Generic Drug Opportunity

In what industry analysts are calling a remarkable regulatory oversight, pharmaceutical company Novo Nordisk reportedly allowed its patent for the popular diabetes and weight loss drug semaglutide to lapse in Canada by failing to pay maintenance fees, according to recent reports. The situation came to light during an interview with Sandoz CEO Richard Saynor, who revealed his company plans to launch a generic version of the GLP-1 drug in Canada as early as 2026.

by Darren Holt
Business

Novo Nordisk Initiates U.S. Layoffs Amid Global Restructuring, Sources Confirm

Pharmaceutical giant Novo Nordisk has commenced a significant round of layoffs in the United States, its most crucial market, according to internal communications and sources familiar with the matter. The job reductions span numerous departments including regulatory affairs, sales, and clinical development as part of a broader global restructuring initiative. The layoffs come as new CEO Mike Doustdar aims to restore investor confidence amid competitive pressures.

U.S. Workforce Reductions Underway

Novo Nordisk has initiated a substantial round of layoffs in the United States, according to reports from internal company communications and sources familiar with the situation. The Danish pharmaceutical company, known for its popular weight-loss medication Wegovy, reportedly began notifying affected U.S. employees this week, with the process expected to continue through late next week.

by Darren Holt